RxDoctor Payments Data

Molly Lombardo, NP

Family · Lake St Louis, MONPI 1083136378

Payments from drug & device makers

$4,970in general payments, 2019–2025

Across 151 payments — averaging $32.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • AstraZeneca$527
  • SK Life Science, Inc.$515
  • Neurocrine Biosciences, Inc.$335
  • Biohaven Pharmaceuticals, Inc.$249
  • MDD US Operations, LLC$200
  • plus $959 from 10 others

What the payments were for

  • Food & beverage$4,970100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,970 in reported general payments places this provider in the 90th percentile of 3,812 family providers in Missouri.

See all family providers in Missouri

Medicare billing

Part B allowed, 2024
$7,296
Medicare patients
73
Services billed
92

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate26$50,648
Emgality PenGalcanezumab-Gnlm25$29,368
UbrelvyUbrogepant14$16,058
Levetiracetam177$6,084
Rivastigmine19$4,745
Carbamazepine12$2,070
Gabapentin90$2,056
Carbidopa-LevodopaCarbidopa/Levodopa67$1,942
Zonisamide15$1,927
Lamotrigine43$1,548
Memantine Hcl79$1,403
Oxcarbazepine19$1,311
Topiramate63$1,054
Donepezil Hcl83$955
Atorvastatin Calcium51$768

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt$167$50,64826 claims
AbbVieUbrelvy$2,186$16,05814 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,812 family providers in Missouri.

Other family in Lake St Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →